Items Tagged ‘lynparza’

January 15, 2018

Lynparza Slows Spread of Inherited Breast Cancer Caused by BRCA Mutations: First Drug Approved for BRCA Breast Cancer

By

CancerConnect News: The US Food and Drug Administration (FDA) has extended the approval of Lynparza (olaparib) to include the treatment of metastatic breast cancer in patients who carry the specific inherited BRCA mutation.  These patients can be identified by using the FDA-approved genetic test, BRACAnalysis CDx (Myriad Genetic Laboratories). About BRCA Breast Cancer Breast cancer […]

View full entry

Tags: brca, Breast Cancer, clinical trial, lynparza, News, olaparib, OlympiAD, PARP Inhibitors


October 10, 2017

LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations

By

LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes also appears to slowe the progression of breast cancer caused in part by mutations in the BRCA gene.  BRCA is an inherited condition that causes up to 3% of all breast cancers. BRCA + breast cancer is particularly […]

View full entry

Tags: BRCA breast cancer, Breast Cancer, lynparza, News, olaparib, PARP inhibitor, Precision Cancer Medicine


May 26, 2015

Olaparib

By

Class: Biological Therapy Generic Name: Olaparib Trade Name: Lynparza™ For which conditions is this drug approved? Lynparza is used treat women with advanced ovarian cancer who have: a) received previous treatment with three or more prior chemotherapy medicines or a combination of chemotherapy medicines; and b) have a certain type of abnormal inherited BRCA gene. […]

View full entry

Tags: Biological Therapy, Drug Dictionary, lynparza, O, Ovarian Cancer, PARP inhibitor